Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Key facts

Study ID

NCT00808678

Run by

AstraZeneca

People needed

90

Starts

2008-12-01

Last updated by the study team

2012-09-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A condition of general good health
• BMI 19 to 29

You may not qualify if…

• Currently enrolled in another clinical study
• Females who are pregnant or breast-feeding

Where it is running

• Site Reference ID/Investigator# 14762 — Orlando, Florida, United States
• Site Reference ID/Investigator# 14762 — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.